Australian Public Assessment Reports (AusPAR)
Search our AusPAR dataset.
An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.
For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Search
6 result(s) found, displaying 1 to 6
-
Australian Public Assessment Report (AusPAR)AusPAR for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) as booster dose for active immunisation to prevent COVID-19
-
Australian Public Assessment Report (AusPAR)AusPAR for Comirnaty Original/Omicron BA.4-5 COVID-19 vaccine (tozinameran and famtozinam) for prevention of COVID-19.
-
Australian Public Assessment Report (AusPAR)AusPAR for Comirnaty Original/Omicron BA.1 COVID-19 vaccine (tozinameran and riltozinameran) for prevention of COVID-19.
-
Australian Public Assessment Report (AusPAR)AusPAR for SPIKEVAX COVID-19 VACCINE (elasomeran) as booster in 12 to 17 years of age for prevention of COVID-19
-
Australian Public Assessment Report (AusPAR)AusPAR for COMIRNATY (tozinameran) for the prevention of COVID-19.
-
Australian Public Assessment Report (AusPAR)Nuvaxovid (SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for prevention of COVID-19 in individuals 12 years of age and older.